Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

The stock's fall snapped a two-day winning streak.

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

This was the stock's second consecutive day of gains.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Recent market volatility has created an attractive entry point for both stocks heading into 2025. Their dividend yields now ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...